This state-of-the-art facility is designed to leverage artificial intelligence (AI) to significantly reduce the time required for drug discovery cycles, accelerating the development of life-changing medicines.
The platform will consist of highly integrated modules, supported by mobile robots, and developed over a two-year period commencing January 2025. By automating and optimising each stage of the DMTA cycle, the system will accelerate identification and development of treatments for a broad spectrum of diseases.
In collaboration with industry leaders the synthesis platform will be designed and built at Labman’s North Yorkshire based HQ, integrating cutting-edge technologies to:
Design - Use AI-driven algorithms to analyse data and design novel drug molecules.
Make - Synthesise, workup, purify and analyse both individual compounds and compound sets with unprecedented precision.
Test - Automate reformatting, selection, and execution of required assays including assay ready plate generation, compound potency testing and efficacy in both cell free and cell based biological assays.
Analyze - Perform comprehensive compound profiling and integrate results back into the design phase to trigger iterative cycles.
This ambitious project underscores Labman’s leadership in delivering innovative automation solutions. The DMTA platform will not only enhance drug discovery but also showcasing the transformative potential of AI and automation in healthcare research.
Ian Riley, Managing Director at Labman, shared his excitement about the project:
For more information, please contact:
[email protected]
[email protected] | 01642 710 580
www.labmanautomation.com